Last reviewed · How we verify

Bevacizumab and Paclitaxel

Central European Cooperative Oncology Group · Phase 3 active Biologic

Bevacizumab and Paclitaxel is a Combination therapy: monoclonal antibody (anti-VEGF) + taxane chemotherapy Biologic drug developed by Central European Cooperative Oncology Group. It is currently in Phase 3 development for Metastatic breast cancer, Non-small cell lung cancer, Ovarian cancer.

Bevacizumab inhibits tumor angiogenesis by blocking VEGF, while paclitaxel stabilizes microtubules to prevent cell division, combining anti-angiogenic and cytotoxic effects.

Bevacizumab inhibits tumor angiogenesis by blocking VEGF, while paclitaxel stabilizes microtubules to prevent cell division, combining anti-angiogenic and cytotoxic effects. Used for Metastatic breast cancer, Non-small cell lung cancer, Ovarian cancer.

At a glance

Generic nameBevacizumab and Paclitaxel
SponsorCentral European Cooperative Oncology Group
Drug classCombination therapy: monoclonal antibody (anti-VEGF) + taxane chemotherapy
TargetVEGF (bevacizumab); beta-tubulin (paclitaxel)
ModalityBiologic
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Bevacizumab is a monoclonal antibody that binds vascular endothelial growth factor (VEGF), preventing new blood vessel formation in tumors. Paclitaxel is a taxane chemotherapy agent that binds to beta-tubulin and stabilizes microtubules, disrupting mitotic spindle formation and inducing apoptosis. Together, they provide complementary mechanisms: bevacizumab starves tumors of blood supply while paclitaxel directly kills cancer cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Bevacizumab and Paclitaxel

What is Bevacizumab and Paclitaxel?

Bevacizumab and Paclitaxel is a Combination therapy: monoclonal antibody (anti-VEGF) + taxane chemotherapy drug developed by Central European Cooperative Oncology Group, indicated for Metastatic breast cancer, Non-small cell lung cancer, Ovarian cancer.

How does Bevacizumab and Paclitaxel work?

Bevacizumab inhibits tumor angiogenesis by blocking VEGF, while paclitaxel stabilizes microtubules to prevent cell division, combining anti-angiogenic and cytotoxic effects.

What is Bevacizumab and Paclitaxel used for?

Bevacizumab and Paclitaxel is indicated for Metastatic breast cancer, Non-small cell lung cancer, Ovarian cancer, Cervical cancer.

Who makes Bevacizumab and Paclitaxel?

Bevacizumab and Paclitaxel is developed by Central European Cooperative Oncology Group (see full Central European Cooperative Oncology Group pipeline at /company/central-european-cooperative-oncology-group).

What drug class is Bevacizumab and Paclitaxel in?

Bevacizumab and Paclitaxel belongs to the Combination therapy: monoclonal antibody (anti-VEGF) + taxane chemotherapy class. See all Combination therapy: monoclonal antibody (anti-VEGF) + taxane chemotherapy drugs at /class/combination-therapy-monoclonal-antibody-anti-vegf-taxane-chemotherapy.

What development phase is Bevacizumab and Paclitaxel in?

Bevacizumab and Paclitaxel is in Phase 3.

What are the side effects of Bevacizumab and Paclitaxel?

Common side effects of Bevacizumab and Paclitaxel include Neutropenia, Peripheral neuropathy, Hypertension, Proteinuria, Bleeding/hemorrhage, Alopecia.

What does Bevacizumab and Paclitaxel target?

Bevacizumab and Paclitaxel targets VEGF (bevacizumab); beta-tubulin (paclitaxel) and is a Combination therapy: monoclonal antibody (anti-VEGF) + taxane chemotherapy.

Related